222. Primary nephrotic syndrome
234 clinical trials,   241 drugs   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02093533
(ClinicalTrials.gov)
March 201417/3/2014Eculizumab in Primary MPGNEVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIAMembranoproliferative GlomerulonephritisDrug: EculizumabMario Negri Institute for Pharmacological ResearchAlexion Pharma Italy s.r.l.CompletedN/A75 YearsAll10Phase 2Italy
2EUCTR2013-003826-10-IT
(EUCTR)
24/01/201428/10/2013ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA - Eculizumab in primary MPGN Membranoproliferative glomerulonephritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]IRCCS- Mario Negri InstituteNULLNot Recruiting Female: yes
Male: yes
10Phase 2Italy
3NCT01221181
(ClinicalTrials.gov)
July 201013/10/2010Eculizumab Therapy for Dense Deposit Disease and C3 NephropathyEculizumab Therapy for Dense Deposit Disease and C3 NephropathyDense Deposit Disease;Membranoproliferative GlomerulonephritisDrug: EculizumabColumbia UniversityAlexion PharmaceuticalsCompleted18 YearsN/AAll6Phase 1United States